- Home
- Heart Failure
Heart Failure
Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice
- 0.75 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments
- Summarise results from ongoing trials with experimental treatments
- Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021
- 0.50 AMA PRA Credit
Published:
Learning objectives
- Identify patients likely to benefit from invasive procedures versus pharmacological treatment
- Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021
- 0.25 AMA PRA Credit
Published:
Learning objectives
- Recall the efficacy and safety of existing HCM treatments
- Summarize results from ongoing trials with experimental treatments
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
- 1.00 MMA
Published:
Learning objectives
- Understand the latest ARNI data in HFpEF and HFrEF
- Understand how emerging data relates to current practice in Malaysia
- Apply current understanding of ARNI therapy in appropriate heart failure patients
Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme
- 1.00 MMA
Published:
Learning objectives
- Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
- List the main clinical implications of cardiac remodelling.
- Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
- Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
- Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
- Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
- 1.00 EBAC
Published:
Learning objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
- Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
- Assess the interrelationships linking diabetes, HF and CVD.
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
